
Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.

Your AI-Trained Oncology Knowledge Connection!


Matthew T. Campbell, MD, MS, discusses CAR T-cell therapy and immunotherapy advances in renal cell carcinoma.

Molecular profiling is a tool that can best determine first-line therapy options for patients with advanced RCC.

Before closing out their discussion on the evolving treatment landscape of advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, highlight clinical trials in the adjuvant setting.

Shared insight on the results from triplet therapy–centered clinical trials in advanced renal cell carcinoma and how these might inform treatment strategies as the paradigm continues to evolve.

Experts Matthew Campbell, MD, MS, and Brian Rini, MD, provide a brief review of recent clinical data in the setting of relapsed/refractory renal cell carcinoma.

A broad look at the data from several recent first-line clinical trials in the setting of advanced renal cell carcinoma and considerations for how they may impact real-world practice.

Closing out their discussion on adverse event management in advanced renal cell carcinoma, Matthew Campbell, MD, MS, and Brian Rini, MD, consider overlapping toxicity in TKI/IO regimens.

Expert perspectives on the most common adverse events seen while managing advanced renal cell carcinoma, followed by advice on how best to manage these and counsel patients.

Comprehensive insight on the factors that help determine optimal first-line therapy for a patient presenting with advanced renal cell carcinoma.

Expert oncologists Matthew Campbell, MD, MS, and Brian Rini, MD, open their discussion on advanced renal cell carcinoma management by defining cornerstone treatment approaches.

Closing their discussion on metastatic urothelial carcinoma, panelists reflect on novel agents and the future treatment paradigm.

Expert perspectives on the selection of second-line therapy after a patient has progressed on maintenance avelumab.

Focused discussion on the duration of maintenance avelumab for metastatic urothelial carcinoma and considerations for switching therapy.

A brief review of whether FGFR status in metastatic urothelial carcinoma should impact treatment approaches.

Shared insight on how best to discuss maintenance therapy with patients being treated for metastatic urothelial carcinoma.

Panelists consider whether the use of maintenance therapy is as prevalent after complete response or in patients with lesser PD-L1 expression.

Experts highlight the benefits of frontline avelumab maintenance therapy in patients with metastatic urothelial carcinoma.

Experts discuss frontline immunotherapy for metastatic urothelial carcinoma when chemotherapy may not be an option.

Shared insight on best practices in frontline maintenance therapy for metastatic urothelial carcinoma to improve patient outcomes.

Reviewing a patient case of metastatic urothelial carcinoma, experts discuss the selection of frontline and maintenance therapy.

Published: December 21st 2021 | Updated:

Published: December 21st 2021 | Updated:

Published: December 5th 2022 | Updated:

Published: December 10th 2021 | Updated:

Published: November 28th 2022 | Updated:

Published: December 10th 2021 | Updated: